Friday, June 21, 2013

Human organs 'could be grown in animals within a year'

http://www.telegraph.co.uk/science/science-news/10132347/Human-organs-could-be-grown-in-animals-within-a-year.html


Human organs 'could be grown in animals within a year'
Japanese scientists are expecting to be granted approval to grow human organs in animals and then harvest them for transplant within the next year.
Surgeons perform a transplant as it was announced today that Japanese scientists are expecting to be granted approval to grow human organs in animals and then harvest them for transplant within the next year Photo: Alamy

By Julian Ryall, Tokyo 2:41PM BST 20 Jun 2013

  A panel of scientists and legal experts appointed by the government has drawn up a recommendation that will form the basis of new guidelines for Japan's world­leading embryonic research.
There is widespread support in Japan for research that has raised red flags in other countries. Scientists plan to introduce a human stem cell into the embryo of an animal – most likely a pig – to create what is termed a "chimeric embryo" that can be implanted into an animal's womb.
That will then grow into a perfect human organ, a kidney or even a heart, as the host animal matures.

When the adult creature is slaughtered, the organ will then be harvested and transplanted into a human with a malfunctioning organ.
"This recommendation is a very important step forward and one that has taken us three years to achieve," Professor Hiromitsu Nakauchi, head of the centre for stem cell biology and regenerative medicine at the University of Tokyo, told The Daily Telegraph.
Prof Nakauchi's team have already succeeded in injecting stem cells from rats into the embryos of mice that had been genetically altered.
"We can apply the same principles to human stem cells and pigs, although the guidelines have not permitted us to do this yet," he said.
At present, the Japanese guidelines permit scientists to develop chimeric embryos in laboratory conditions for a maximum of 14 days, but the next stage in the process – the embryos being implanted into an animal's womb – is prohibited.
As soon as government officials agree on the details of the revised guidelines – a process that is expected to take 12 months – Prof Nakauchi believes the first pig carrying a human organ can be produced "quite quickly, because the technique has been established already."
The scientists plan to initially breed a pig with a human pancreas as it is a relatively easy organ to create, Prof. Nakauchi said, and perfecting the technique will bring relief to millions of people with diabetes.
Creating kidneys and a human heart will be far more complicated, he said, but are feasible. He suggested that practical use for the organs may be as little as five years away.
Eventually, he hopes to be able to have numerous human organs within each donor animal that can be harvested all at the same time.
© Copyright of Telegraph Media Group Limited 2013 

Monday, April 15, 2013

Researchers develop implantable, bioengineered rat kidney (w/ video)

http://medicalxpress.com/news/2013-04-implantable-bioengineered-rat-kidney-video.html



Researchers develop implantable, bioengineered rat kidney (w/ video)

April 14th, 2013 in Medical research 
Mass. General team develops implantable, bioengineered rat kidney

Removal of all living cells from a rat kidney leaves a collagen scaffolding, ready for repopulation with new kidney and vascular cells. Credit: Massachusetts General Hospital Center for Regenerative Medicine.
Bioengineered rat kidneys developed by Massachusetts General Hospital (MGH) investigators successfully produced urine both in a laboratory apparatus and after being transplanted into living animals. In their report, receiving advance online publication in Nature Medicine, the research team describes building functional replacement kidneys on the structure of donor organs from which living cells had been stripped, an approach previously used to create bioartificial hearts, lungs and livers.
"What is unique about this approach is that the native organ's architecture is preserved, so that the resulting graft can be transplanted just like a  and connected to the recipient's vascular and urinary systems," says Harald Ott, MD, PhD, of the MGH Center for Regenerative Medicine, senior author of the Nature Medicine article. "If this technology can be scaled to human-sized grafts, patients suffering from  who are currently waiting for donor kidneys or who are not  could theoretically receive new organs derived from their own ."
This video is not supported by your browser at this time.
Around 18,000 kidney transplants are performed in the U.S. each year, but 100,000 Americans with end-stage  are still waiting for a . Even those fortunate enough to receive a transplant face a lifetime of , which pose many health risks and cannot totally eliminate the incidence of eventual .
The approach used in this study to engineer donor organs, based on a technology that Ott discovered as a research fellow at the University of Minnesota, involves stripping the living cells from a donor organ with a detergent solution and then repopulating the collagen scaffold that remains with the appropriate cell type – in this instance  to replace the lining of the vascular system and kidney cells from newborn rats. The research team first decellularized rat kidneys to confirm that the organ's complex structures would be preserved. They also showed the technique worked on a larger scale by stripping cells from pig and human kidneys.
Making sure the appropriate cells were seeded into the correct portions of the collagen scaffold required delivering vascular cells through the renal artery and  through the ureter. Precisely adjusting the pressures of the solutions enabled the cells to be dispersed throughout the whole organs, which were then cultured in a bioreactor for up to 12 days. The researchers first tested the repopulated organs in a device that passed blood through its vascular system and drained off any urine, which revealed evidence of limited filtering of blood, molecular activity and urine production.
Mass. General team develops implantable, bioengineered rat kidney
This is a previously decellularized rat kidney after reseeding with endothelial cells, to repopulate the organ's vascular system, and neonatal kidney cells. Credit: Massachusetts General Hospital Center for Regenerative Medicine
Bioengineered kidneys transplanted into living rats from which one kidney had been removed began producing urine as soon as the blood supply was restored, with no evidence of bleeding or clot formation. The overall function of the regenerated organs was significantly reduced compared with that of normal, healthy kidneys, something the researchers believe may be attributed to the immaturity of the neonatal cells used to repopulate the scaffolding.
"Further refinement of the cell types used for seeding and additional maturation in culture may allow us to achieve a more functional organ," says Ott. "Based on this inital proof of principle, we hope that bioengineered kidneys will someday be able to fully replace kidney function just as donor kidneys do. In an ideal world, such grafts could be produced 'on demand" from a patient's own cells, helping us overcome both the organ shortage and the need for chronic immunosuppression. We're now investigating methods of deriving the necessary cell types from patient-derived cells and refining the cell-seeding and organ culture methods to handle human-sized organs."
Ott's team focuses on the regeneration of hearts, lungs, kidneys and grafts made of composite tissues, while other teams – including one from the MGH Center for Engineering in Medicine – are using the decellularization technique to develop replacement livers. Lead author of the Nature Medicine paper is Jeremy Song, MGH Center for Regenerative Medicine; additional co-authors are Jacques Guyette, PhD, Sarah Gilpin, PhD, Gabriel Gonzalez, PhD, and Joseph Vacanti, MD, all of the MGH Center for Regenerative Medicine. The study was supported by National Institute of Health Director's New Innovator Award DP2 OD008749-01.
More information: dx.doi.org/10.1038/nm.3154
Provided by Massachusetts General Hospital
"Researchers develop implantable, bioengineered rat kidney (w/ video)." April 14th, 2013. http://medicalxpress.com/news/2013-04-implantable-bioengineered-rat-kidney-video.html

Thursday, May 24, 2012

Skin cells turned into stem cells to repair heart.


Tuesday, May 22, 2012

2 studies find a link between sleep apnea & cancer



Two new studies have found that people with sleep apnea, have a higher risk of cancer. the condition deprives the body of oxygen at night and often coincides with cardiovascular disease, obesity and diabetes. In one of the new studies, researchers in Spain followed thousands of patients at sleep clinics and found that those with the most severe forms of sleep apnea had a 65 percent greater risk of developing cancer of any kind. The second study, of about 1,500 government workers in Wisconsin, showed that those with the most breathing abnormalities at night had five times the rate of dying from cancer as people without the sleep disorder. Both research teams only looked at cancer diagnoses and outcomes in general, without focusing on any specific type of cancer.
In both studies, being presented in San Francisco this week at an international conference organized by the American Thoracic Society, the researchers ruled out the possibility that the usual risk factors for cancer, like age, smoking, alcohol use, physical activity and weight, could have played a role. The association between cancer and disordered breathing at night remained even after they adjusted these and other variables. The studies were observational, and other, unknown factors may account for the correlation between sleep apnea and cancer. Recent animal studies have suggested that sleep apnea might play a role in cancer. When mice with tumors were placed in low-oxygen environments that simulate the effects of sleep apnea, their cancers progressed more rapidly. Scientists speculate that depriving mice of oxygen may cause their bodies to develop more blood vessels to compensate, an effect that could act as a kind of fertilizer for cancer tissue and cause tumors to grow and spread more quickly.
The researchers wondered whether a similar relationship might exist in people with sleep apnea, in whom throat muscles collapse during sleep, choking off the airway and causing gasping and snoring as the body fights for air. Severe sleep apnea can produce hundreds of such episodes each night, depleting the body of oxygen.
In one study, a team at the University of Wisconsin School of Medicine and Public Health examined data on state workers taking part in the long-running Wisconsin Sleep Cohort, who since 1989 have undergone extensive overnight sleep studies and other measures of health about every four years. The landmark project was one of the first to reveal the widespread occurrence of sleep apnea in the general population.
The researchers found that the more severe a person’s breathing problems at night, the greater the likelihood of dying from cancer. People with moderate apnea were found to die of cancer at a rate double that of people without disordered breathing at night, while those in the severe category died at a rate 4.8 times that of those without the sleep disorder. In the second study, researchers with the Spanish Sleep Network took a slightly different approach, looking not at cancer mortality among apnea patients, but at the incidence of cancer. They used a measure called the hypoxemia index, which looks at the amount of time the level of oxygen in a person’s blood drops below 90 percent at night.
About 5,200 people were followed for seven years, none of whom had a cancer diagnosis when the study began. The researchers found that the greater the extent of hypoxemia, or oxygen depletion, during sleep, the more likely a person would receive a cancer diagnosis during the study period.
People whose oxygen levels dropped below 90 percent for up to 12 percent of the total time they were asleep, for example, had a 68 percent greater likelihood of developing cancer than people whose oxygen levels did not plummet at night, said study author Dr. Miguel Angel Martinez-Garcia of La Fe University and Polytechnic Hospital in Spain. As time spent without oxygen increased, so, too, did cancer risk.
Although the study did not look for it, Dr. Martinez-Garcia speculated that treatments for sleep apnea like continuous positive airway pressure, or CPAP, which keeps the airways open at night, might reduce the association.
The Wisconsin study also did not specifically look at the impact of treatment for apnea on survival, either, but when people who were being treated with CPAP were removed from the analysis, the cancer association became stronger, “which is consistent with the hypoxemia theory,” Dr. Nieto said.

Sunday, September 25, 2011

Scientists 'seed' cells, make new organs

http://www.cnn.com/2011/HEALTH/03/07/building.new.urethras/index.html

By Stephanie Smith, CNN Medical Producer

March 7, 2011 6:41 p.m. EST


(CNN) -- Engineering organs begins with something missing -- a phantom organ in the body that causes a patient incredible discomfort, dysfunction or pain. It ends with a Star Trek-esque feat of engineering where missing organs are replaced using cells culled from a patient's own body.
In a small pilot study, published Monday in the Lancet, scientists reported successfully reconstructing urethras in five young patients, using their own cells.
"We were able to create patients' own tissue that actually belongs there," said Dr. Anthony Atala, lead author of the study and director of the Institute for Regenerative Medicine at Wake Forest University School of Medicine. "If the tissue is supposed to be there, hopefully we will do better by the patient."
Patients had their engineered urethras implanted between March 2004 and July 2007 at the Federico Gomez Children's Hospital in Mexico City. Their urethras continued to function after several years' follow-up.
The urethra is a narrow tube that connects the bladder with the genitals, providing a conduit to usher waste out of the body. When it is damaged -- sometimes congenitally, or as result of disease, pelvic fractures or other traumas -- it is usually replaced using tissue harvested from the lining of a patient's cheeks or using skin grafted from another area of the body, according to Atala.
"Unfortunately for the narrow structures in the body (like urethras), they are kind of complex because they tend to collapse," said Atala, who added that conventional urethra replacement fails more than half the time. "Every organ has its own challenges."
The challenge with traditional urethra replacement is creating a viable tube, one that will not easily collapse. And that is where engineering urethras may offer some benefit.
The first step for engineering a new urethra is to take a very small piece of the patient's own tissue (around half the size of a postage stamp) from the bladder area. Cells are scraped from the biopsied tissue, allowed to multiply, after which muscle cells are separated from urethral cells.
It is the next few steps in the process that sound like science fiction. When there are a sufficient number of cells, scientists "seed" them -- much like you would seed a new lawn -- onto a mesh scaffold that is shaped like a urethra. The inside of the mesh is coated with urethral cells while the outside gets muscle cells.
"It's like baking a layer cake, but doing it one layer at a time," said Atala.
The seeded structure is placed in an incubator for about two weeks, in a "cooking" process that Atala says simulates how cell growth occurs inside the body. After that, the newly engineered urethra is ready to be implanted into the patient.
"During the surgery, we go to the area that has been damaged, clean out scar tissue and plug in a new, engineered urethra," said Atala. "It sounds easy but it is a fairly complex surgical procedure. This is a narrow structure and it has to fit just right."
According to the study, the engineered grafts appeared normal about three months after they were implanted. Patients' urethras functioned normally within a few weeks after surgery and maintained that function for up to six years.
"This is an exciting study showing that tissue engineering can be a viable option for complex urethral repairs," said David A. Vorp, a professor of bioengineering and cardiothoracic surgery at the University of Pittsburgh, who was not involved with this study. "It shows that the patient's own cells can be utilized, which will eliminate the possibility of rejection."
Vorp added that biopsies carry their own risks, such as infection and other complications, and that the study needs to be replicated in a larger study group. Although the current study had few patients enrolled, Vorp said it represents "a significant step toward an important new means for urethral repair."
Atala concedes that it will be several years before engineering organs becomes the norm, and that it is not yet clear whether this same technology will work in adults. He said that in addition to patients with urethra dysfunction, patients with other, complex small vessel problems -- such as blood vessels that collapse after heart bypass surgery -- could one day profit from this technology.
"There is a huge population with small vessel disease where the vessels keep collapsing and occluding," said Atala. "The main concept here is a narrow tubularized, complex structure that doesn't collapse long-term."
Atala and colleagues reported similar success in seven spina bifida patients to replace their dysfunctional bladders in 2006. Scientists at Wake Forest have successfully engineered more than 30 tissues and organs, including miniature livers, heart valves -- even printing organs such as human skin and kidneys -- in the lab.
Scientists like Atala say regenerative medicine represents a new frontier in medicine that could see doctors curing, rather than merely treating, diseases using the body's natural ability to heal itself. Autologous cells -- or cells that come from a patient's own body -- allow organs to be transplanted without rejection.
Still, all of that is many years away. Most of these burgeoning technologies are not yet ready for widespread implantation, and the cost of regenerative medicine at this early juncture is often much higher than conventional procedures.
"An interesting challenge with a lot of these technologies and with regenerative medicine is you have to go slow," said Atala. "The key is to go slow and have long-term follow-up. Keep patient safety first."

Wednesday, June 22, 2011

Stem Cell Breakthrough: Pigs could grow human organs

http://au.ibtimes.com/articles/167205/20110622/stem-cell-breakthrough-pigs-could-grow-human-organs.htm

Wednesday, June 22, 2011 10:54 AM EST

Stem Cell Breakthrough: Pigs could grow human organs

By G.G. Denia
At the annual conference of the European Society of Human Genetics, Professor Hiromitsu Nakauchi, director of the center for stem cell biology and regenerative medicine at the University of Tokyo in Japan, led the new stem cell research breakthrough.  Professor Nakauchi called the new technique as blastocyst complementation.
The technique included injecting stem cells from rats into the embryos or blastocysts of mice that could not grow their own organs. Results have shown that the mice were indeed able to grow rat organ.
Professor Nakauchi said: "Our ultimate goal is to generate human organs from induced pluripotent stem cells.
"The technique, called blastocyst complementation, provides us with a novel approach for organ supply. We have successfully tried it between mice and rats. We are now rather confident in generating functional human organs using this approach."  Furthermore, he said they hoped to further test the technique by growing other organs and were also seeking permission to utilize human stem cells.
He said: "For ethical reasons we cannot make an organ deficient human embryo and use it for blastocyst complementation.
"So to make use of this system to generate human organs, we must use this technique using blastocysts of livestock animals such as pigs instead."
"Blastocyst complementation across species had never been tested before, but we have now shown that it can work."
The researchers, apparently, already managed to produce pigs that were able to generate human blood by injecting blood stem cells from humans into pig fetuses.
Stem cells are said to be biological cells found in all multi-cellular organisms, divide through mitosis or cell division and differentiate into diverse specialized cell types. This self-renewing capability to produce more stem cells could provide the abundant supply or organs for transplant with possible minimized risk for transplant rejection.

Sunday, May 22, 2011

Test that tells you how long you'll live


DNA testing

The £400 test that tells you how long you'll live

DNA breakthrough heralds new medical era – and opens ethical Pandora's box
By Steve Connor, Science Editor
Monday, 16 May 2011
http://www.independent.co.uk/news/science/the-163400-test-that-tells-you-how-long-youll-live-2284639.html

A blood test that can show how fast someone is ageing – and offers the tantalising possibility of estimating how long they have left to live – is to go on sale to the general public in Britain later this year.
The controversial test measures vital structures on the tips of a person's chromosomes, called telomeres, which scientists believe are one of the most important and accurate indicators of the speed at which a person is ageing.
Scientists behind the €500 (£435) test said it will be possible to tell whether a person's "biological age", as measured by the length of their telomeres, is older or younger than their actual chronological age.
Medical researchers believe that telomere testing will become widespread within the next five or 10 years, but there are already some scientists who question its value and whether there should be stronger ethical controls over its wider use. In addition to concerns about how people will react to a test for how "old" they really are, some scientists are worried that telomere testing may be hijacked by unscrupulous organisations trying to peddle unproven anti-ageing remedies and other fake elixirs of life.
The results of the tests might also be of interest to companies offering life-insurance policies or medical cover that depend on a person's lifetime risk of falling seriously ill or dying prematurely. However, there is a growing body of scientific opinion that says testing the length of a person's telomeres could provide vital insights into the risk of dying prematurely from a range of age-related disorders, from cardiovascular disease to Alzheimer's and cancer. "We know that people who are born with shorter telomeres than normal also have a shorter lifespan. We know that shorter telomeres can cause a shorter lifespan," said Maria Blasco of the Spanish National Cancer Research Centre in Madrid, who is the inventor of the new commercial telomere test. "But we don't know whether longer telomeres are going to give you a longer lifespan. That's not really known in humans," she added.
"What is new about this test is that it is very precise. We can detect very small differences in telomere length and it is a very simple and fast technique where many samples can be analysed at the same time. Most importantly, we are able to determine the presence of dangerous telomeres – those that are very short."
Dr Blasco's company, Life Length, is in talks with medical diagnostic companies across Europe, including the UK, to market the test and collect blood samples for analysis in Spain. A deal with a company operating in Britain is likely within a year, she said.
"We need to have a clinical company to send us the blood [samples]. We are in contact with several groups in the UK who are interested," Dr Blasco said.
Life Length is anticipating hundreds of requests from people wanting to have their telomeres tested and is expecting demand from thousands more once the company is able to bring down the cost of the test as public demand increases.
Although Life Length is not the only company selling telomere tests, it is the only one gearing up for over-the-counter sales to the public and the only company with an accurate-enough test to be of practical use, said Professor Jerry Shay of the University of Texas Southwestern Medical Centre in Dallas.
"This test devised by Blasco is so accurate that it is likely to provide more useful information than some of the other tests out there right now," said Professor Shay, who is a scientific consultant for Life Length. "What's important in ageing is the shortest telomeres. What makes cells stop growing is the shortest telomeres, not the average telomere length, which is what other tests look at.
"Everyone talks about the chronological age, but there is also a biological age, and telomere length is actually a pretty good representation of your biological age. Telomeres are important – there is no question of that," he said.
Asked why the general public would be interested in taking a telomere test, Dr Shay said: "I think people are just basically curious about their own mortality. If you ask people what they worry about, most people would say they are worried about dying."
He added: "People might say 'If I know I'm going to die in 10 years I'll spend all my money now', or 'If I'm going to live for 40 more years I'll be more conservative in my lifestyle'. The worrying thing is that if this information ever got to a point where it is believable, insurance companies would start requiring it in terms of insuring people.
"If you smoke or you're obese your insurance rates are higher, and if you have short telomeres your insurance rates might be higher too."
Scientists do not yet believe they can narrow down the test prediction to calculate the exact number of months and years a person has yet to live, but several studies have indicated that individuals with telomeres that shorter than normal are likely to die younger than those with longer telomeres. Telomere research is considered to be one of the most exciting areas in biomedical science and last year the Nobel Prize in medicine was shared between three scientists who are pioneers in the field.
Interestingly, one of the Nobel laureates, Elizabeth Blackburn of the University of California San Francisco, is an enthusiastic proponent of telomere testing while another of the prize-winners, Carol Greider of Harvard Medical School, is more sceptical of its benefits.
"Do I think it's useful to have a bunch of companies offering to measure telomere length so people can find out how old they are? No," Dr Greider recently told the journal Science.
Dr Blasco, a former post-doctoral student in Dr Greider's laboratory, is more certain of the benefits. "It will be useful for you to know your biological age and maybe to change your lifestyle habits if you find you have short telomeres," she said.
Telomeres: a short history
* 2003 Scientists studying 20-year-old blood samples from 143 people show that telomere length is good indicator of whether someone is likely to live for 15 years or more once they reach 60.
* 2004 Women living with stress of having a sick child are found to have shorter telomeres. Other research suggests that meditation or other forms of stress reduction may lengthen telomeres.
* 2007 Study of men in Scotland shows those with the longest telomeres were half as likely to develop heart disease than those with shorter telomeres. Telomere length was as good as cholesterol levels at predicting the risk of developing cardiovascular disease.
* 2009 Short telomeres linked with inherited bone marrow disease.
* 2010 GM mice with no telomerase, an enzyme that elongates telomeres in some cells, age prematurely compared to normal mice. The ageing effects were reversed after injections of telomerase.
* 2011 Study of civil servants in the UK shows that those with few educational qualifications have shorter telomeres than those with higher educational qualifications. People with poor backgrounds are known to age faster and suffer more age-related diseases.

Cancer Cure?

http://hubpages.com/hub/Scientists_cure_cancer__but_no_one_takes_notice



Canadian researchers find a simple cure for cancer, but major pharmaceutical companies are not interested.

Researchers at the University of Alberta, in Edmonton, Canada have cured cancer last week, yet there is a little ripple in the news or in TV. It is a simple technique using very basic drug. The method employs dichloroacetate, which is currently used to treat metabolic disorders. So, there is no concern of side effects or about their long term effects.

This drug doesn’t require a patent, so anyone can employ it widely and cheaply compared to the costly cancer drugs produced by major pharmaceutical companies.

Canadian scientists tested this dichloroacetate (DCA) on human’s cells; it killed lung, breast and brain cancer cells and left the healthy cells alone. It was tested on Rats inflicted with severe tumors; their cells shrank when they were fed with water supplemented with DCA. The drug is widely available and the technique is easy to use, why the major drug companies are not involved? Or the Media interested in this find?

In human bodies there is a natural cancer fighting human cell, the mitochondria, but they need to be triggered to be effective. Scientists used to think that these mitochondria cells were damaged and thus ineffective against cancer. So they used to focus on glycolysis, which is less effective in curing cancer and more wasteful. The drug manufacturers focused on this glycolysis method to fight cancer. This DCA on the other hand doesn’t rely on glycolysis instead on mitochondria; it triggers the mitochondria which in turn fights the cancer cells.

The side effect of this is it also reactivates a process called apoptosis. You see, mitochondria contain an all-too-important self-destruct button that can't be pressed in cancer cells. Without it, tumors grow larger as cells refuse to be extinguished. Fully functioning mitochondria, thanks to DCA, can once again die.

With glycolysis turned off, the body produces less lactic acid, so the bad tissue around cancer cells doesn't break down and seed new tumors.

Pharmaceutical companies are not investing in this research because DCA method cannot be patented, without a patent they can’t make money, like they are doing now with their AIDS Patent. Since the pharmaceutical companies won’t develop this, the article says other independent laboratories should start producing this drug and do more research to confirm all the above findings and produce drugs. All the groundwork can be done in collaboration with the Universities, who will be glad to assist in such research and can develop an effective drug for curing cancer.

This article wants to raise awareness for this study, hope some independent companies and small startup will pick up this idea and produce these drugs, because the big companies won’t touch it for a long time.

Monday, January 24, 2011

Exercise: In Women, Weight Training for a Sharper Mind

http://www.nytimes.com/2010/01/26/health/research/26exer.html?_r=1
January 26, 2010
VITAL SIGNS


By RONI CARYN RABIN
Older women who did an hour or two of strength training exercises each week had improved cognitive function a year later, scoring higher on tests of the brain processes responsible for planning and executing tasks, a new study has found.

Researchers in British Columbia randomly assigned 155 women ages 65 to 75 either to strength training with dumbbells and weight machines once or twice a week, or to a comparison group doing balance and toning exercises.

A year later, the women who did strength training had improved their performance on tests of so-called executive function by 10.9 percent to 12.6 percent, while those assigned to balance and toning exercises experienced a slight deterioration — 0.5 percent. The improvements in the strength training group included an enhanced ability to make decisions, resolve conflicts and focus on subjects without being distracted by competing stimuli.

Older women are generally less likely than others to do strength training, even though it can promote bone health and counteract muscle loss, said Teresa Liu-Ambrose, a researcher at the Center for Hip Health and Mobility at Vancouver General Hospital and the lead author of the paper, which appears in the Jan. 25 issue of Archives of Internal Medicine.

Blocking Rogue Gene Could Stop Spread of Cancer, New Research Suggests

http://www.sciencedaily.com/releases/2011/01/110124073903.htm

ScienceDaily (Jan. 24, 2011) — Scientists at the University of East Anglia (UEA) have discovered a rogue gene involved in the spread of cancer in the body. By blocking the gene, they believe, cancer could be stopped in its tracks.

Published in the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.

The culprit gene -- known as WWP2 -- is an enzymic bonding agent found inside cancer cells. It attacks and breaks down a natural inhibitor in the body which normally prevents cancer cells spreading. The UEA team found that by blocking WWP2, levels of the natural inhibitor are boosted and the cancer cells remain dormant.If a drug was developed that deactivated WWP2, conventional therapies and surgery could be used on primary tumours, with no risk of the disease taking hold elsewhere.

Lead author Andrew Chantry, of UEA's School of Biological Sciences, said the discovery could lead to the development of a new generation of drugs within the next decade that could be used to stop the aggressive spread of most forms of the disease, including breast, brain, colon and skin cancer.
"The late-stages of cancer involve a process known as metastasis -- a critical phase in the progression of the disease that cannot currently be treated or prevented," said Dr Chantry.
"The challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene. This is a difficult but not impossible task, made easier by the deeper understanding of the biological processes revealed in this study."
The research was funded by UK-based charity the Association of International Cancer Research (AICR), with additional support from the Big C Charity and the British Skin Foundation.
Dr Mark Matfield, scientific co-ordinator of AICR, said: "This is a very exciting new discovery and a perfect example of the way that basic research into cancer can open up ways to develop new ways to treat cancer."
The initial discovery was made while researchers were studying a group of natural cancer cell inhibitors called 'Smads'.
Dr Surinder Soond, who spearheaded the experimental work in the laboratory, said: "This is a very novel and exciting approach to treating cancer and the spread of tumours which holds great potential."

Tuesday, December 7, 2010

Daily Aspirin Cuts Many Cancer Risks

http://www.foxnews.com/health/2010/12/07/study-daily-aspirin-cuts-cancer-risks/#ixzz17RlnbXiH

Published December 07, 2010 | Reuters


Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.
The findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.

In a study of eight trials involving 25,570 patients, researchers found that cancer deaths among those who took aspirin in doses as low as 75 milligrams a day were 21 percent lower during the studies and 34 percent lower after five years.
Aspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.

Peter Rothwell of Britain's Oxford University said that while taking aspirin carries a small risk of stomach bleeding, that risk was beginning to be "drowned out" by its benefits in reducing the risk of cancer and the risk of heart attacks.
"Previous guidelines have rightly cautioned that in healthy middle-aged people the small risk of bleeding on aspirin partly offsets the benefit from prevention of strokes and heart attacks, but the reductions in deaths due to several common cancers will now alter this balance for many people," he said.

His suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.
"REMARKABLE DRUG"

Aspirin, originally developed by Bayer, is a cheap over-the-counter drug used for pain and to reduce fever.
Previous studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.

Alastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists' understanding of how to prevent cancer.
"It is further proof that aspirin is, by a long way, the most amazing drug in the world," he said.

In Rothwell's study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for esophageal cancer in those taking aspirin.

Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.
The researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.

Peter Elwood, an expert on aspirin from Cardiff University's medical school who was not involved in this study, described aspirin as "a remarkable drug". "This risk of a bleed is so small compared to the benefits," he told reporters. "Yes, okay, it's a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial."

Friday, December 3, 2010

Mercury poisoning makes male birds homosexual


01 December 2010 by Michael Marshall


Low levels of mercury in the diet of male white ibises cause the birds to mate with each other rather than with females. As a result many of the females can't breed, and fewer chicks are produced.

It's the first time a pollutant has been found to change an animal's sexual preference. Many chemicals can "feminise" males or reduce fertility, but males affected in these ways still prefer females.

Mercury is extremely toxic, particularly in the form of methylmercury, which reduces breeding in wild birds by disrupting their parenting behaviours. To find out if it also affected mating, Peter Frederick of the University of Florida in Gainesville and Nilmini Jayasena of the University of Peradeniya, Sri Lanka, captured 160 young white ibises from south Florida. They gave them food laced with methylmercury and monitored them closely.

The birds were split into four groups. One group ate food with 0.3 parts per million methylmercury, which most US states would regard as too high for human consumption. A second group got 0.1 ppm, and the third 0.05 ppm, a low dose that wild birds would be exposed to frequently. The fourth group received none.

Poisoned

All three dosed groups had significantly more homosexual males than the control group. Male-male pairs courted, built nests together and paired off for several weeks. Higher doses increased the effect, with 55 per cent of males in the 0.3 ppm group affected. Male-male matings were responsible for 81 per cent of unproductive nests in the dosed groups.

Meanwhile the heterosexual pairs courted less and were bad at parenting – patterns of behaviour that were both already known to be caused by methylmercury poisoning. The combined effects of male-male pairing and poor performance by male-female pairs could be severe. "In the worst-case scenario, the production of young would fall by 50 per cent," says Frederick.

Looking for effects on courtship and mating is novel, says Tony Scheuhammer of Environment Canada's National Wildlife Research Center in Ottawa, Ontario. "People normally study pairs that have already mated to see how good they are at parenting," he says.

Other birds would probably be similarly affected, though both Frederick and Scheuhammer say it's far from clear whether other animal groups would be. In particular, there's no evidence for increased homosexuality in humans resulting from mercury poisoning, despite several long-term studies. "If the effect was as strong in humans as in the ibises, they'd have found it," Frederick says.

Journal reference: Proceedings of the Royal Society B, DOI: 10.1098/rspb.2010.2189

Spray-On Stem Cells Speed Healing Process For Burn Victims

http://www.care2.com/causes/health-policy/blog/spray-on-stem-cells-accelerate-healing-for-burn-victims/




An experimental stem cell treatment is helping to speed up the healing process for burn victims, according to researchers at the University of Utah.

We've all heard of spray-on tans, and (ahem) clothing, but now the same principle of instant-application is being used to provide a speedy recovery process for those that are suffering from serious burns.

In clinical trials, surgeons Amit Patel and Amalia Cochran are testing "a concentrate of [the patient's own] platelets and progenitor cells with calcium and thrombin to create a Jello-like substance accelerates the healing process".

Popular Science reports that "in tests, the spray has proven effective in the treatment of small burns and seems to improve the likelihood that a skin graft will take, which could carry positive implications for the application of this technology to other types of transplants."


A similar treatment, called ReCell, is already being used in Australia, Europe and China and made headlines when it was used to treat of victims of a 2002 bombing in Bali.

So far, the spray-on treatment is only being used on patients with small burns, but the researchers hope that someday they maybe able to scale up the process to treat those who sustain burns on large areas of their body, like military personnel or people that have been caught in a house fire.

Monday, November 29, 2010

Harvard scientists reverse the aging process in mice – now for humans


http://www.guardian.co.uk/science/2010/nov/28/scientists-reverse-ageing-mice-humans

Harvard scientists reverse the ageing process in mice – now for humans
Harvard scientists were surprised that they saw a dramatic reversal, not just a slowing down, of the ageing in mice. Now they believe they might be able to regenerate human organs


Ian Sample, science correspondent
guardian.co.uk, Sunday 28 November 2010 18.01 GMT


In mice, reactivating the enzyme telomerase led to the repair of damaged tissues and reversed the signs of ageing. Photograph: Robert F. Bukaty/AP
Scientists claim to be a step closer to reversing the ageing process after rejuvenating worn out organs in elderly mice. The experimental treatment developed by researchers at Harvard Medical School turned weak and feeble old mice into healthy animals by regenerating their aged bodies.

The surprise recovery of the animals has raised hopes among scientists that it may be possible to achieve a similar feat in humans – or at least to slow down the ageing process.

An anti-ageing therapy could have a dramatic impact on public health by reducing the burden of age-related health problems, such as dementia, stroke and heart disease, and prolonging the quality of life for an increasingly aged population.

"What we saw in these animals was not a slowing down or stabilisation of the ageing process. We saw a dramatic reversal – and that was unexpected," said Ronald DePinho, who led the study, which was published in the journal Nature.

"This could lead to strategies that enhance the regenerative potential of organs as individuals age and so increase their quality of life. Whether it serves to increase longevity is a question we are not yet in a position to answer."

The ageing process is poorly understood, but scientists know it is caused by many factors. Highly reactive particles called free radicals are made naturally in the body and cause damage to cells, while smoking, ultraviolet light and other environmental factors contribute to ageing.

The Harvard group focused on a process called telomere shortening. Most cells in the body contain 23 pairs of chromosomes, which carry our DNA. At the ends of each chromosome is a protective cap called a telomere. Each time a cell divides, the telomeres are snipped shorter, until eventually they stop working and the cell dies or goes into a suspended state called "senescence". The process is behind much of the wear and tear associated with ageing.

At Harvard, they bred genetically manipulated mice that lacked an enzyme called telomerase that stops telomeres getting shorter. Without the enzyme, the mice aged prematurely and suffered ailments, including a poor sense of smell, smaller brain size, infertility and damaged intestines and spleens. But when DePinho gave the mice injections to reactivate the enzyme, it repaired the damaged tissues and reversed the signs of ageing.

"These were severely aged animals, but after a month of treatment they showed a substantial restoration, including the growth of new neurons in their brains," said DePinho.

Repeating the trick in humans will be more difficult. Mice make telomerase throughout their lives, but the enzyme is switched off in adult humans, an evolutionary compromise that stops cells growing out of control and turning into cancer. Raising levels of telomerase in people might slow the ageing process, but it makes the risk of cancer soar.

DePinho said the treatment might be safe in humans if it were given periodically and only to younger people who do not have tiny clumps of cancer cells already living, unnoticed, in their bodies.

David Kipling, who studies ageing at Cardiff University, said: "The goal for human tissue 'rejuvenation' would be to remove senescent cells, or else compensate for the deleterious effects they have on tissues and organs. Although this is a fascinating study, it must be remembered that mice are not little men, particularly with regard to their telomeres, and it remains unclear whether a similar telomerase reactivation in adult humans would lead to the removal of senescent cells."

Lynne Cox, a biochemist at Oxford University, said the study was "extremely important" and "provides proof of principle that short-term treatment to restore telomerase in adults already showing age-related tissue degeneration can rejuvenate aged tissues and restore physiological function."

DePinho said none of Harvard's mice developed cancer after the treatment. The team is now investigating whether it extends the lifespan of mice or enables them to live healthier lives into old age.

Tom Kirkwood, director of the Institute for Ageing and Health at Newcastle University, said: "The key question is what might this mean for human therapies against age-related diseases? While there is some evidence that telomere erosion contributes to age-associated human pathology, it is surely not the only, or even dominant, cause, as it appears to be in mice engineered to lack telomerase. Furthermore, there is the ever-present anxiety that telomerase reactivation is a hallmark of most human cancers."

Thursday, November 18, 2010

Merck cholesterol drug extremely effective in study

http://www.reuters.com/article/idUSN1719543320101117

Wed, Nov 17 2010
* Raises good HDL cholesterol 138 pct
* Cuts bad LDL cholesterol 40 pct in patients on statins
* No safety or torcetrapib-like problems observed
* 30,000-patient outcomes study to begin in 2011 Q2
By Bill Berkrot and Ransdell Pierson
NEW YORK/CHICAGO, Nov 17 (Reuters) - An experimental Merck & Co (MRK.N: Quote, Profile, Research, Stock Buzz) heart drug, from a class of medicine with a troubled past, appeared to be safe and had a "jaw dropping" effect on both good and bad cholesterol levels, according to data from a clinical trial.
Merck's anacetrapib increased good HDL levels by a stunning 138 percent after 24 weeks of treatment, and lowered levels of bad LDL cholesterol by 40 percent in patients already taking LDL-lowering statins, researchers said.
"The lipid effects are jaw dropping in both directions," said Dr. Christopher Cannon, the study's lead investigator from Brigham and Women's Hospital in Boston. He presented the data at the American Heart Association scientific meeting in Chicago on Wednesday.
Researchers found no anacetrapib safety issues during the 18-month study, and patients receiving the drug had fewer serious heart problems than those given a placebo.
Even if development of the medicine continues without a hitch, it will likely be at least five years before Merck can begin selling the drug.
Anacetrapib belongs to a class of drugs called CETP inhibitors that produced one of the most spectacular clinical failures in pharmaceutical history. A pivotal study of Pfizer Inc's (PFE.N: Quote, Profile, Research, Stock Buzz) highly touted torcetrapib was stopped in late 2006 after higher death rates were found among those taking the drug, pulling the plug on an $800 million Phase III program.
Based on the data from the anacetrapib trial, called Define, "we are 94 percent confident that anacetrapib doesn't have the clinical (side) effects of torcetrapib," Cannon said.
The HDL increase seen with anacetrapib "is double what torcetrapib does; it's four times what niacin can do if you can push niacin to its full 2 gram dose; and 10 times the effect seen with statins," Cannon said, comparing anacetrapib with other therapies.
It is believed that HDL has a heart protective effect, possibly by carrying LDL away from the arteries.
Anacetrapib also cut by 36 percent levels of LP(a), which is believed to be an independent cardiovascular risk factor.
The 1,623-patient, 18-month Define trial was designed to show anacetrapib does not have the unintended effects on blood chemistry and blood pressure found in detailed analyses of what went wrong with the Pfizer drug.
"It's been found that torcetrapib unfortunately as a molecule somehow lands itself in the adrenal gland and then pumps out aldosterone, other hormones, and has all these effects," Cannon explained.
Compared with the placebo group, patients receiving anacetrapib in the study showed no difference in electrolytes, aldosterone or blood pressure, and no other safety concerns were seen with the drug, he said.
"This trial was set up so that we would have some more reassurance that the drug was safe before doing a gigantic trial. And that's what we found, that it looks safe so far," Cannon said.
In the wake of torcetrapib, Merck has long known that to gain approval for anacetrapib, it will have to conduct a large so-called outcomes trial to prove its drug cuts heart attacks and death rather than just impacts cholesterol levels.
Plans for such a study were announced on Wednesday. It will include some 30,000 patients at high risk of heart attack or other serious heart problems, and take about four years to complete. Enrollment is expected to begin in the second quarter of 2011, researchers said.
Patients in the 18-month Define study all had coronary disease or were at high risk for heart disease, and were already taking a statin, such as Lipitor, to lower their LDL levels. They received either 100 milligrams of anacetrapib or a placebo once a day on top of their statin.
At the start of the study, patients on average had a baseline HDL of 40 and LDL of 81. Those on anacetrapib on average saw HDL leap to 101 and LDL drop to 45. HDL levels of placebo patients rose only to 46, while LDL fell to 77.
Patients whose LDL dropped below 25 were taken off the drug as a precaution, which was part of the study's design. "We didn't see any problems, but this gets the LDL down as low as its ever been in any study," Cannon said.
Researchers observed a trend toward lower rates of cardiovascular death, heart attack, stroke and hospitalization for unstable angina. The need for angioplasty or bypass surgery over 18 months was significantly lower on anacetrapib -- eight patients versus 28 on placebo.
While the dramatic impact on HDL is clear, it remains to be determined if raising it through the CETP inhibitor mechanism can save lives and hospitalizations.
Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) and Japan Tobacco (2914.T: Quote, Profile, Research, Stock Buzz) are also forging ahead with development of a CETP inhibitor, called dalcetrapib.
"There is very real uncertainty as to what anacetrapib will do on clinical outcomes," said Rory Collins, co-director of the clinical trial service unit at the University of Oxford, who will lead the outcomes study program.
"It is incredibly exciting. It could be really the next big thing in cardiovascular disease," Collins said. (Reporting by Bill Berkrot and Randell Pierson; editing by John Wallace)

Monday, November 1, 2010

Researchers Grow a Liver in a Lab Setting




Researchers have created a buzz in the organ transplant world by growing a liver in a lab setting. However, this liver may function just like any other liver but it is miniature, a test to see if the technology was possible. The group used stem cells to create the liver which is said to be genetically identical to that of a human liver.
The idea that human organs can be grown in labs has been the stuff of science fiction novels for years. However, it has become a reality these days. Still, the researchers have said that it will be years before the technology and science are advanced far enough to create full size organs.
When the advancements are complete it will revolutionize the transplant world. Patients will no longer have to wait years for a new organ when one can be specifically grown for them in a lab setting.
One issue is the fact that these organs are designed by using stem cell research. This gives them a specific DNA structure that must be unique to the patient. Stem cell research has only recently restarted in the US after President Obama lifted a ban imposed by former President Bush.
Organ transplants are a hot commodity in this world today. Black markets buy and sell organs through underground medical facilities, often causing fatalities when the patients develop infections from unsterile conditions.
With the advancement of lab grown organs research may be able to save the lives of millions every year.

Short URL: http://thenewsportalonline.com/?p=3946

Thursday, August 26, 2010

Brain Connections Break Down as We Age, Study Suggests



http://www.sciencedaily.com/releases/2010/08/100818151822.htm


The circled portion of the older adult' brain on the left indicates the cross-talk between the two hemispheres that is not apparent in the younger brain on the right. Click above image for higher resolution. (Credit: Rachael Seidler)
ScienceDaily (Aug. 19, 2010) — It's unavoidable: breakdowns in brain connections slow down our physical response times as we age, a new study suggests.

This slower reactivity is associated with an age-related breakdown in the corpus callosum, a part of the brain that acts as a dam during one-sided motor activities to prevent unwanted connectivity, or cross-talk, between the two halves of the brain, said Rachael Seidler, associate professor in the University of Michigan School of Kinesiology and Department of Psychology, and lead study author.

At other times the corpus callosum acts at a bridge and cross-talk is helpful, such as in certain cognitive functions or two-sided motor skills.

The U-M study is the first known to show that this cross-talk happens even while older adults are at rest, said Seidler, who also has appointments in the Institute of Gerontology and the Neuroscience Graduate Program. This resting cross-talk suggests that it is not helpful or compensatory for the two halves of the brain to communicate during one-sided motor movements because the opposite side of the brain controls the part of the body that is moving. So, when both sides of the brain talk simultaneously while one side of the body tries to move, confusion and slower responses result, Seidler said.

Previous studies have shown that cross-talk in the brain during certain motor tasks increases with age but it wasn't clear if that cross-talk helped or hindered brain function, said Seidler.

"Cross-talk is not a function of task difficulty, because we see these changes in the brain when people are not moving," Seidler said.

In some diseases where the corpus callosum is very deteriorated, such as in people with multiple sclerosis, you can see "mirror movements" during one sided-motor tasks, where both sides move in concert because there is so much communication between the two hemispheres of the brain, Seidler said. These mirror movements also happen normally in very young children before the corpus callosum is fully developed.

In the study, researchers gave joysticks to adults between the ages of 65 and 75 and measured and compared their response times against a group approximately 20-25 years old.

Researchers then used a functional MRI to image the blood-oxygen levels in different parts of the brain, a measurement of brain activity.

"The more they recruited the other side of the brain, the slower they responded," Seidler said.

However there is hope, and just because we inevitably age doesn't mean it's our fate to react more slowly. Seidler's group is working on developing and piloting motor training studies that might rebuild or maintain the corpus callosum to limit overflow between hemispheres, she said.

A previous study done by another group showed that doing aerobic training for three months helped to rebuild the corpus callosum, she said, which suggests that physical activity can help to counteract the effects of the age-related degeneration.

Seidler's group also has a study in review that uses the same brain imaging techniques to examine disease related brain changes in Parkinson's patients.

The study appeared in the journal Frontiers in Systems Neuroscience.